本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/12/21 | | | --- | --- | --- | | 回购方案实施期限 | 自公司第二届董事会第七次会议审议通过之日起 | | | | 12 个月内 | | | 预计回购金额 | 500 万元 | 万元~1,000 | | 回购用途 | | □减少注册资本 | | | √用于员工持股计划或股权激励 | | | | □用于转换公司可转债 | | | | □为维护公司价值及股东权益 | | | 累计已回购股数 | 122.8955 | 万股 | | 累计已回购股数占总股本比 | 0.4479% | | | 例 | | | | 累计已回购金额 | 799.74 | 万元 | | 实际回购价格区间 | 5.45 元/股 | 元/股~9.24 | 一、 回购股份的基本情况 湖南南新制药股份有限公司（以下简称"公司"）于 2023 年 12 月 20 日召开 第二届董事会第七次会议，审议通过了《关于以集中竞价交易方式回购公司 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥111,835,236.68, representing a decrease of 63.12% compared to the same period last year[5]. - The net profit attributable to shareholders for Q1 2024 was ¥3,766,508.55, down 69.95% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,292,851.63, a decline of 79.62% compared to the previous year[5]. - The basic earnings per share for Q1 2024 was ¥0.0137, reflecting a decrease of 70.02% year-on-year[5]. - Net profit for Q1 2024 was ¥4,677,245.81, a decline of 67.4% from ¥14,364,549.60 in Q1 2023[19]. - Operating profit for Q1 2024 was ¥4,554,127.43, down 75.5% from ¥18,595,451.64 in Q1 2023[19]. - Basic and diluted earnings per share for Q1 2024 were both ¥0.0137, compared to ¥0.0457 in Q1 2023[20]. Cash Flow - The net cash flow from operating activities was ¥36,863,557.07, an increase of 1,280.20% compared to the same period last year[5]. - Cash flow from operating activities for Q1 2024 was ¥36,863,557.07, an increase from ¥2,670,878.86 in Q1 2023[22]. - The company reported a net cash decrease of ¥18,419,625.64 in Q1 2024, contrasting with an increase of ¥43,681,456.52 in Q1 2023[23]. - Total cash outflow from financing activities in Q1 2024 was ¥47,973,027.73, compared to ¥11,800,772.25 in Q1 2023[22]. - Cash and cash equivalents at the end of Q1 2024 were ¥543,309,757.82, down from ¥757,153,421.15 at the end of Q1 2023[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,695,297,794.00, down 2.43% from the end of the previous year[6]. - As of March 31, 2024, the total current assets amounted to RMB 1,245,613,160.93, a decrease from RMB 1,290,011,027.37 as of December 31, 2023, reflecting a decline of approximately 3.5%[14]. - The company's cash and cash equivalents were RMB 644,597,429.05, down from RMB 665,760,897.54, indicating a decrease of about 3.3%[13]. - Accounts receivable stood at RMB 522,624,553.81, a slight decrease from RMB 543,961,786.48, representing a decline of approximately 3.9%[13]. - The total liabilities decreased to RMB 396,291,492.81 from RMB 435,210,026.70, marking a reduction of about 8.9%[15]. - The total assets as of March 31, 2024, were RMB 1,695,297,794.00, down from RMB 1,737,536,466.45, reflecting a decrease of approximately 2.4%[15]. - The company's non-current assets totaled RMB 449,684,633.07, slightly up from RMB 447,525,439.08, indicating a marginal increase of about 0.5%[14]. - The total equity attributable to shareholders decreased to RMB 1,313,885,150.78 from RMB 1,318,116,026.60, a decline of approximately 0.3%[15]. Research and Development - Research and development expenses totaled ¥16,512,853.64, a decrease of 51.46% year-on-year, while the R&D expense ratio to operating revenue increased by 3.55 percentage points to 14.77%[6]. - Research and development expenses for Q1 2024 were ¥6,826,875.34, significantly reduced from ¥34,015,766.79 in Q1 2023[18]. Market Strategy - The company adjusted its sales strategy in response to market conditions, leading to a decline in sales prices of some core products, which contributed to the decrease in revenue[8]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,051[10].

公司及公司监事会对涂凤鸣女士在任职工代表监事期间为公司发展所做出 的贡献表示衷心的感谢。 证券代码：688189 证券简称：南新制药 公告编号：2024-022 湖南南新制药股份有限公司 关于职工代表监事退休离任及补选职工代表监事的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖南南新制药股份有限公司（以下简称"公司"）监事会于近日收到职工代 表监事涂凤鸣女士的书面辞职报告。涂凤鸣女士因已届法定退休年龄，已办理完 成退休离任手续，并申请辞去公司职工代表监事职务，其辞职后将不在公司及子 公司担任职务。涂凤鸣女士职工代表监事职务的原定任期为公司第二届监事会任 期届满之日止。截至本公告披露日，涂凤鸣女士未持有公司股票，亦不存在应当 履行而未履行的承诺事项。 李晓霞，1988 年 8 月出生，中国国籍，中共党员，无境外永久居留权，中山 大学会计学专业毕业，本科学历，中级会计师职称。2011 年 11 月至 2016 年 9 月 就职于广州市大震机电设备有限公司，2018 年 6 月至 2021 年 1 月就职于广州市 番禺 ...

上 海 证 券 交 易 所 上证科创公监函〔2024〕0014 号 张世喜，湖南南新制药股份有限公司时任总经理暨法定代表 人； 李 亮，湖南南新制药股份有限公司时任财务总监； 李 旋，湖南南新制药股份有限公司时任董事会秘书。 经查明，2024 年 1 月 31 日，湖南南新制药股份有限公司（以下 简称公司）披露 2023 年年度业绩预告，预计公司 2023 年度扣非后 归母净利润区间为-500 万元至 500 万元。2 月 29 日，公司披露 2023 年度业绩快报，预计公司2023年度扣非后归母净利润为468.47万元， 业绩快报同时披露尚未发现影响本次业绩快报内容准确性的重大不 确定因素。 2024 年 3 月 26 日，公司披露 2023 年度业绩快报更正公告称， 公司 2023 年度扣非后归母净利润由 468.47 万元修正为 1,107.74 万元， 并披露差异的形成原因主要是经公司与审计机构沟通，确认因公司 1 关于对湖南南新制药股份有限公司 及有关责任人予以监管警示的决定 当事人： 湖南南新制药股份有限公司，A 股证券简称：南新制药，A 股证 券代码：688189； 胡新保，湖南南新制药股份有限 ...

关于湖南南新制药股份有限公司 首次公开发行股票并在科创板上市之保荐总结报告书 湖南南新制药股份有限公司（以下简称"南新制药"、"公司"或"上市公司"） 于2020 年 3月26日首次公开发行股票并在科创板上市。西部证券股份有限公司（以下 简称"保荐人"或"西部证券"）担任南新制药首次公开发行股票并在科创板上市的 保荐人，负责南新制药上市后的持续督导工作，持续督导期至2023年12月31日。目前， 持续督导期限已届满。 截至 2023年 12 月 31 日，南新制药首次公开发行的募集资金尚未使用完毕，保荐 人将对其募集资金使用情况继续履行持续督导义务。 根据《证券发行上市保荐业务管理办法 》（2023年2月修订）《上海证券交易所 科创板股票上市规则（2023年8月修订）》等相关法规和规范性文件的要求，保荐人 出具本保荐总结报告书。 一、保荐人及保荐代表人承诺 （一）保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导性 陈述或重大遗漏，保荐人及保荐代表人对其真实性、准确性、完整性承担法律责任。 西部证券股份有限公司 （二）保荐人及保荐代表人自愿接受中国证监会对保荐总结报告书相关事项进行 的任何质询和调 ...

西部证券股份有限公司 关于湖南南新制药股份有限公司 2023年度持续督导跟踪报告 西部证券股份有限公司（以下简称"西部证券"或"保荐人"）作为湖南南新制 药股份有限公司（以下简称"南新制药"或"公司"）首次公开发行股票并在科创 板上市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则（2023年8月修订）》《上海证券交易所科创板上市公司自律监管指引 第1号——规范运作（2023年12月修订）》以及《上海证券交易所上市公司自律监管 指引第11号——持续督导 （2023年8月修订）》等有关规定，负责南新制药上市后的 持续督导工作，并出具本持续督导跟踪报告。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针对 | 保荐人已建立健全并有效执行了持 续督导制度，并制定了相应的工作 | | | 具体的持续督导工作制定相应的工作计划。 | 计划。 | | 2 | 根据中国证监会相关规定，在持续督导工作开始 | 保荐人已与南新制药签订承销与保 | | | 前，与上市公司或相关当事人签署持续督导协议 | 荐 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/12/21 | | | --- | --- | --- | | 回购方案实施期限 | 12 | 自公司第二届董事会第七次会议审议通过之日起 个月内 | | 预计回购金额 | 500 | 万元~1,000 万元 | | 回购用途 | | 用于员工持股计划或股权激励 | | 累计已回购股数 | 122.8955 | 万股 | | 累计已回购股数占总股本比例 | 0.4479% | | | 累计已回购金额 | 799.74 | 万元 | | 实际回购价格区间 | 5.45 | 元/股~9.24 元/股 | 一、回购股份的基本情况 公司于 2023 年 12 月 20 日召开第二届董事会第七次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司以不低于人民币 500 万 元（含）且不超过人民币 1,000 万元（含）的自有资金或自筹资金，通过集中竞 价交易方式回购公司人民币普通股（A 股）股票，在未来适宜时 ...

证券代码：688189 证券简称：南新制药 公告编号：2024-021 湖南南新制药股份有限公司 持股 5%以上股东大宗交易减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本公告披露日，广州乾元投资管理企业（有限合伙）（以下简称"广州 乾元"）直接持有湖南南新制药股份有限公司（以下简称"南新制药"或"公司"） 43,120,000 股，占公司总股本的 15.71%。 上述股份来源于公司首次公开发行前取得的股份及公司实施资本公积转增 股本相应增加的股份，且已于 2021 年 3 月 26 日起解除限售并上市流通。 减持计划的主要内容 因股东自身资金需求，广州乾元计划通过大宗交易方式合计减持公司股份不 超过 5,488,000 股，不超过公司股份总数的 2.00%。广州乾元本次减持股份自本 公告披露之日起 3 个交易日后的 3 个月内进行，且在任意连续 90 日内减持股份 的总数不超过公司股份总数的 2.00%。减持价格将按照减持实施时的市场价格确 定。 ...

Financial Performance - The company reported no cash dividends or stock bonuses for the 2023 fiscal year, with the profit distribution plan requiring approval from the annual shareholders' meeting [6]. - The company has not achieved profitability since its listing, indicating ongoing financial challenges [4]. - A standard unqualified audit report was issued by the accounting firm, ensuring the accuracy of the financial statements [5]. - The company achieved operating revenue of CNY 744.60 million in 2023, an increase of 6.55% compared to CNY 698.83 million in 2022 [25]. - The net profit attributable to shareholders was CNY 3.75 million in 2023, a significant recovery from a net loss of CNY 78.83 million in 2022 [25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 11.08 million, compared to a loss of CNY 89.31 million in the previous year [25]. - The company reported a net cash flow from operating activities of CNY 215.23 million, a turnaround from a negative cash flow of CNY 160.09 million in 2022 [25]. - Basic earnings per share turned positive to CNY 0.0137 in 2023, compared to a loss of CNY 0.2873 in 2022 [26]. - The total assets decreased by 11.11% to CNY 1,737.54 million at the end of 2023, down from CNY 1,954.61 million at the end of 2022 [25]. - The weighted average return on net assets increased to 0.29% in 2023, up from -5.82% in 2022, marking a significant improvement [26]. Research and Development - The company is currently in the process of developing new products and technologies, although specific details are not provided in the available documents [14]. - The company has 22 new products in development, including 7 innovative drug projects and 13 generic drug projects [39]. - The company has increased its R&D investment as a percentage of operating revenue to 12.51% in 2023, up from 9.22% in 2022 [26]. - The company has filed for 3 new invention patents and received 3 new authorizations, bringing the total to 35 authorized patents [39]. - The company is conducting clinical trials for a modified new drug, Palivizumab inhalation solution, which aims to be the world's first nebulized anti-influenza drug [44]. - The company is focusing on the development of innovative drugs for children and rare diseases, supported by recent regulatory changes aimed at accelerating the approval process for these types of medications [54]. - The company is enhancing its core technologies, including drug lead compound design and discovery, which are crucial for new drug development, and has successfully developed a multi-target kinase inhibitor with intellectual property rights [57]. - The company has established a comprehensive new drug research and development system covering all stages from target analysis to clinical research [74]. Market and Product Strategy - The company attributed its revenue growth to increased sales of antiviral drugs due to respiratory disease outbreaks and optimized sales strategies [27]. - The company is actively expanding its marketing network and sales channels, focusing on OTC markets and enhancing brand awareness [41]. - The company is planning new product launches to create additional revenue and profit growth points [41]. - The company is focusing on expanding its product line in the fields of fever and pain relief, with several generic drug applications submitted [45]. - The company is expanding its product line in the cardiovascular and respiratory disease sectors, with existing products including exclusive antihypertensive and cholesterol-lowering medications, and is preparing to submit applications for new generic drugs [53]. - The company is actively involved in the research and development of radiopharmaceuticals, which play a critical role in diagnosing and treating various diseases, and is reforming the approval process for these products [56]. Risk Management and Corporate Governance - The company emphasizes the importance of risk factors in its forward-looking statements, urging investors to be cautious [7]. - The management team has committed to ensuring the authenticity and completeness of the financial report, reflecting a focus on corporate governance [6]. - The report includes a risk statement regarding forward-looking statements, highlighting potential uncertainties in future plans [7]. - The company is subject to the two-invoice system, which may impact its distribution and sales strategies [14]. - The company has implemented cost control measures, resulting in a turnaround from loss to profit in its operating performance [38]. - The company faces risks related to the approval of new drugs, with existing products like Palivizumab facing potential competition from generics [80]. - The company is exposed to macroeconomic risks, including the impact of national volume-based procurement policies, which have led to significant price reductions for pharmaceuticals [83]. Shareholder and Board Activities - The company held four shareholder meetings during the reporting period, all resolutions were passed without any being rejected [149]. - The company approved the appointment of financial auditing institutions for the year 2022 and 2023 [149]. - The company has proposed a profit distribution and capital reserve transfer plan for the year 2022 [149]. - The company reported no changes in the shareholding of directors and senior management during the reporting period [151]. - The company’s independent directors provided their annual performance reports during the meetings [149]. - The company appointed new non-independent directors and independent directors during the 2023 shareholder meetings, establishing a new board for a three-year term [156]. - The company’s major shareholder changed from Energy Investment Group to Pharmaceutical Development Group in February 2023 [154]. - The company held its second extraordinary general meeting in June 2023, where new board members were elected, including Hu Xinbao as chairman and Zhang Shixi as general manager [156]. Future Outlook - The company provided guidance for the next fiscal year, expecting revenue growth of 10% to 12% [159]. - New product launches are anticipated to contribute an additional 300 million yuan in revenue next year [159]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million yuan allocated for this purpose [159]. - The company aims to increase capital operations through a dual strategy of "internal growth and external expansion," focusing on mergers and acquisitions to steadily enhance industry scale [136]. - The company plans to accelerate innovation and R&D efforts, including the establishment of a key technology platform for inhalation formulations and the pursuit of new national patents [137].

湖南南新制药股份有限公司 独立董事关于公司第二届董事会第八次会议 相关事项的独立意见 作为湖南南新制药股份有限公司（以下简称"公司"）的独立董事，根据《公 司法》《公司章程》和《独立董事工作制度》等有关规定，本着认真、负责的态 度，基于独立、审慎、客观的立场，我们对公司第二届董事会第八次会议审议的 相关事项进行了认真审核，并发表如下独立意见： 一、关于公司 2023 年度内部控制评价报告的独立意见 经核查，我们认为：公司根据相关法律、法规及规范性文件要求，结合自身 实际情况，建立了较为完善的内控体系并有效执行。公司《2023 年度内部控制评 价报告》客观地反映了公司内部控制的真实情况，不存在内部控制设计和执行的 重大缺陷。因此，我们同意该报告。 二、关于公司部分募集资金投资项目延期的独立意见 经核查，我们认为：公司部分募投项目延期是公司根据募投项目实施过程的 内外部实际情况做出的审慎决定，符合公司实际经营情况，不会对公司的正常经 营产生重大不利影响。该延期事宜不涉及项目实施主体、募集资金投资用途及投 资规模的变更，不存在改变或变相改变募集资金投向情形，不存在损害公司和全 体股东尤其是中小股东利益的情形，本次变 ...